Peptide Side Effects by Body System: What Studies Report

The word peptide covers an enormous range of molecules, from approved injectable medicines to unapproved research chemicals. The published safety literature is distributed just as unevenly. Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide have been examined in large randomised trials, pooled meta-analyses and pharmacovigilance analyses, while many peptides circulating in wellness and fitness settings have no comparable controlled safety data at all. This page organises what the peer-reviewed sources listed in the references actually reported, grouped by body system. This page is for educational purposes only and is not medical advice; consult a licensed physician about any symptom, medication or health decision.

What the cited literature covers — and what it does not

Every effect described below comes from a specific cited paper about a specific compound. None of it generalises to peptides as a class. A finding about semaglutide is a finding about semaglutide; a finding about tirzepatide is a finding about tirzepatide. Where a body system has attracted public interest but no coverage in the verified sources, that gap is stated plainly rather than filled with speculation.

Gastrointestinal Effects: What Studies Report

Gastrointestinal tolerability is the single most consistently documented safety theme in the incretin literature. A 2025 systematic review and meta-analysis published in Gastroenterology pooled randomised trials of GLP-1 receptor agonists and reported that gastrointestinal adverse events occurred significantly more often on active treatment than on placebo (PMID 40499738). A separate 2025 systematic review and meta-analysis restricted to people with obesity but without diabetes compared semaglutide and tirzepatide against placebo and likewise reported gastrointestinal events as the leading tolerability problem in that population (PMID 40189856).

Nausea

In a systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes, researchers reported greater weight reduction than placebo alongside a higher frequency of gastrointestinal adverse events, with nausea among the most commonly recorded (PMID 36578889). A 2021 review devoted specifically to the safety of semaglutide described gastrointestinal complaints, nausea foremost among them, as the most frequently observed adverse effects across the development programme (PMID 34305810). A multidisciplinary expert consensus published in 2022 set out clinical recommendations for managing gastrointestinal adverse events in patients treated with GLP-1 receptor agonists, describing gradual dose escalation and dietary adjustment among the mitigation strategies clinicians discussed (PMID 36614945).

Diarrhoea, vomiting and constipation

The 2025 Gastroenterology meta-analysis reported diarrhoea and constipation alongside nausea and vomiting among the pooled gastrointestinal signals attributed to GLP-1 receptor agonists (PMID 40499738). For the dual GIP/GLP-1 agonist tirzepatide, a 2023 meta-analysis of adverse events reported that gastrointestinal complaints including nausea, diarrhoea and vomiting were the most frequent and appeared related to the dose administered (PMID 36789109). A 2023 systematic review of tirzepatide's weight-loss efficiency and safety similarly reported that gastrointestinal events accounted for most treatment discontinuations in the trials examined (PMID 37141329).

Less common but more serious gastrointestinal events

A 2023 analysis published in JAMA examined a claims database of people using GLP-1 receptor agonists for weight loss and reported increased rates of pancreatitis, bowel obstruction and gastroparesis compared with bupropion-naltrexone (PMID 37796527). A 2024 case report described colonic ischaemia occurring in a patient receiving tirzepatide, illustrating the kind of rare event that case literature surfaces before controlled data can quantify it (PMID 39507503). An earlier review of adverse effects of GLP-1 receptor agonists discussed pancreatitis as a long-standing area of pharmacovigilance attention for the class (PMID 26177483).

Cardiovascular Effects: What Studies Report

Cardiovascular outcomes have been a recurring theme in incretin safety reviews rather than a headline adverse-event category. The 2021 semaglutide safety review examined cardiovascular findings alongside gastrointestinal, pancreatic and ophthalmic considerations in its assessment of the compound's overall safety profile (PMID 34305810). The 2014 review of adverse effects of GLP-1 receptor agonists also discussed cardiovascular considerations as part of the class's risk-benefit picture (PMID 26177483). A 2024 review of GLP-1 receptor agonists for obesity addressed weight-loss outcomes together with tolerability, side effects and risks, framing cardiovascular considerations within that broader balance (PMID 39286601). None of the verified sources summarised here characterised cardiac effects of non-incretin peptides, so nothing in this section can be extended to other compounds.

Cancer Signals in the Literature: What Studies Report

Public interest in peptides and cancer largely traces back to preclinical rodent findings and post-marketing surveillance questions rather than to demonstrated human outcomes. The 2014 review of GLP-1 receptor agonist adverse effects discussed the debate around pancreatic and thyroid malignancy signals attributed to the class, describing them as areas of ongoing scrutiny (PMID 26177483). The 2021 semaglutide safety review likewise addressed thyroid C-cell tumour findings from rodent studies among the safety domains it examined (PMID 34305810). Neither source described a settled human causal relationship, and the verified literature summarised here contains no oncology data on peptides outside the incretin class.

Mood and Mental Health: What Studies Report

None of the verified sources summarised on this page reported psychiatric or mood endpoints as a primary outcome. The semaglutide and tirzepatide safety syntheses cited above were structured around gastrointestinal, metabolic and general tolerability outcomes rather than validated mood instruments (PMID 34305810, PMID 37141329). That absence is itself informative: claims circulating about peptides and mood, in either direction, are not supported or refuted by the papers listed here. Anyone evaluating that question would need to look to psychiatric outcome literature and regulatory safety reviews, which fall outside the scope of this page.

Hair and Hair Growth: What Studies Report

A 2025 review of the dermatological profile of GLP-1 agonists catalogued cutaneous and appendageal findings associated with these drugs, including reports of hair shedding and alopecia described in the context of rapid weight reduction (PMID 40422559). The review presented these as reported associations drawn from case-level and observational sources rather than quantified trial endpoints. Topical cosmetic peptides marketed for scalp or hair applications are a separate category entirely, and no verified source cited here evaluated them.

Skin: What Studies Report

The same 2025 dermatology review described injection-site reactions, hypersensitivity phenomena and changes in facial and body soft tissue appearance following substantial weight loss among the dermatological findings reported in association with GLP-1 agonist therapy (PMID 40422559). Injection-site reactions were also noted as a recognised local tolerability issue for GLP-1 receptor agonists in the earlier adverse-effects review (PMID 26177483). Cosmetic "skin peptides" in topical formulations — copper tripeptides, signal peptides and similar ingredients — were not evaluated in any of the verified sources, and the injectable literature says nothing about them.

Weight-Loss Context: What Studies Report

In the weight-loss setting, adverse events and efficacy were reported side by side. The semaglutide meta-analysis in obesity without diabetes reported significant weight reduction relative to placebo together with a higher incidence of gastrointestinal adverse events (PMID 36578889). The tirzepatide systematic review reported weight reduction alongside dose-related gastrointestinal intolerance as the principal safety consideration (PMID 37141329). The 2024 obesity review examined weight-loss outcomes, tolerability, side effects and risks together, emphasising that the class's benefits and its adverse-event burden were inseparable parts of the same clinical assessment (PMID 39286601).

Dose dependence and the escalation period

Two patterns recur across the incretin safety literature. First, gastrointestinal events were reported as dose-related in the tirzepatide adverse-event meta-analysis (PMID 36789109). Second, the expert consensus on managing gastrointestinal adverse events described these complaints as typically most prominent during dose escalation and often attenuating thereafter, which is why gradual titration featured in its recommendations (PMID 36614945). Specific dosing decisions belong to prescribing clinicians and are outside the scope of an educational summary.

Bodybuilding and Fitness Context: What Studies Report

Peptides discussed in bodybuilding and physique settings — growth hormone secretagogues, repair peptides and similar compounds — are largely absent from the verified literature summarised here. Many are supplied as research-use-only materials that have not been approved for human therapeutic use, and research-use-only status means a substance has not undergone the regulatory review that produces a documented adverse-event profile. The consequence is straightforward: the detailed tolerability data available for semaglutide and tirzepatide, such as the pooled gastrointestinal findings reported in the 2025 meta-analysis (PMID 40499738), exist because those compounds went through large controlled trials. Where no such programme exists, absence of reported side effects reflects absence of study, not evidence of safety.

How to read adverse-event data critically

• Source type matters. A pooled meta-analysis of randomised trials (PMID 40189856) supports different conclusions than a single case report (PMID 39507503).
• Comparators matter. The 2023 JAMA analysis measured GLP-1 agonist events against an active weight-loss comparator rather than against no treatment (PMID 37796527).
• Populations matter. The 2025 gastrointestinal safety review specifically studied people with obesity and without diabetes (PMID 40189856).
• Compound specificity matters. Findings for one peptide do not transfer to another with a different receptor target.

Readers weighing any of this against a personal situation should raise it with a licensed physician who can assess individual history, concurrent medications and monitoring needs.

References

• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis (Gastroenterology, 2025)
• Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta-analysis (Annals of Saudi Medicine, 2025)
• Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus (Journal of Clinical Medicine, 2022)
• Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (JAMA, 2023)
• Adverse Events Related to Tirzepatide (Journal of the Endocrine Society, 2023)
• Adverse Effects of GLP-1 Receptor Agonists (Review of Diabetic Studies, 2014)
• Tirzepatide-Associated Colonic Ischemia (ACG Case Reports Journal, 2024)
• Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks (Obesity Pillars, 2024)
• Weight loss efficiency and safety of tirzepatide: A Systematic review (PLoS One, 2023)
• A Closer Look at the Dermatological Profile of GLP-1 Agonists (Diseases, 2025)